Earnings Preview: Regulus Therapeutics
Regulus Therapeutics (NASDAQ:RGLS) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Regulus Therapeutics will report an earnings per share (EPS) of $-0.05.
Regulus Therapeutics bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
Last quarter the company missed EPS by $0.00, which was followed by a 5.63% drop in the share price the next day.
Here's a look at Regulus Therapeutics's past performance and the resulting price change:
|Quarter||Q4 2021||Q3 2021||Q2 2021||Q1 2021|
|Price Change %||-5.63%||-3.98%||-3.85%||7.32%|
Shares of Regulus Therapeutics were trading at $0.1718 as of May 10. Over the last 52-week period, shares are down 67.43%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.